Novo Nordisk Sharpens Its Outlook But Warns Risks Remain Later In 2017
A robust first quarter allowed the Danish diabetes fighter to tighten its guidance - but things are likely to get bumpier for the troubled group as the year progresses.
A robust first quarter allowed the Danish diabetes fighter to tighten its guidance - but things are likely to get bumpier for the troubled group as the year progresses.